Summary
Danaher Corporation reported solid performance in the second quarter and first half of 2022, with overall revenues increasing by 7.5% and 9.5% respectively, driven by a 9.5% and 10.5% increase in core sales. The company navigated persistent challenges like supply chain disruptions and inflationary pressures by effectively leveraging its Danaher Business System (DBS) tools, which largely mitigated adverse impacts on profitability. Despite a 4.5% and 3.5% negative impact from currency translation due to a strong U.S. dollar, the company demonstrated resilience across its key segments, particularly in Life Sciences and Diagnostics. While net earnings saw a slight decrease year-over-year for the three-month period ($1,680 million vs. $1,699 million) and remained relatively flat for the six-month period ($3,405 million vs. $3,401 million), the company maintained strong operating profit margins. The report also highlights the company's strategic acquisitions, which contributed to revenue growth, and its ongoing commitment to investing in organic growth initiatives and operational efficiency. Danaher is closely monitoring global economic conditions, including rising interest rates and geopolitical events like the Russia-Ukraine conflict, and has taken measures to mitigate associated risks.
Financial Highlights
50 data points| Revenue | $6.53B |
| Cost of Revenue | $3.08B |
| Gross Profit | $4.01B |
| R&D Expenses | $420.00M |
| SG&A Expenses | $2.15B |
| Operating Income | $1.89B |
| Interest Expense | $42.00M |
| Net Income | $1.66B |
| EPS (Basic) | $2.28 |
| EPS (Diluted) | $2.25 |
| Shares Outstanding (Basic) | 728.50M |
| Shares Outstanding (Diluted) | 737.40M |
Key Highlights
- 1Total revenues increased by 7.5% for Q2 2022 and 9.5% for the first six months of 2022 compared to the prior year periods.
- 2Core sales, excluding acquisitions and currency impacts, grew by a robust 9.5% in Q2 and 10.5% in the first six months of 2022, indicating strong underlying business momentum.
- 3The company effectively managed supply chain disruptions and inflation through its Danaher Business System (DBS), largely mitigating adverse impacts on profitability.
- 4Despite a negative impact of 4.5% and 3.5% from currency translation (due to a strong USD), overall revenue growth remained positive across key segments.
- 5The Diagnostics segment showed particularly strong core sales growth, up 12.5% in Q2 and 17.5% year-to-date, driven by COVID-19 molecular diagnostic tests and other clinical lab solutions.
- 6The company completed two small acquisitions totaling $77 million in the first half of 2022, which complement its Life Science and Environmental & Applied Solutions segments.
- 7Operating profit margins remained strong, increasing by 60 basis points to 28.4% for Q2 2022, demonstrating effective cost management and pricing power.